Study investigates US ethnic gap in CT recruits

21 January 2008

An investigation into the gap in clinical trial enrollment rates for Caucasians and African Americans in the USA has confirmed the presence of a significant level of distrust on the part of the latter group. Researchers at Johns Hopkins University in Baltimore, Maryland, found blacks were 40% less likely to be willing to register for what was in fact a mock clinical study.

The survey was conducted at 13 medical facilities in Maryland, with 717 patients, about one third of whom were black. While a quarter of whites said they believed physicians would use experimental drugs on patients without their consent, 58% of African Americans believed the need for their consent would be ignored.

Although the gap in patient trust across ethnic lines was less striking in some other survey questions, 25% and 28%, respectively, of African Americans said they thought their own doctor would enroll them in a study that might harm them or would willingly expose patients to unnecessary risks. The equivalent levels of distrust among Caucasian patients were 15% and 22%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight